Formulary Digital Edition October 2009

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their formularies.

If approved, Wegovy would be the first oral GLP-1 drug to treat obesity.

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Insurance hurdles and the complexities of prior authorization create barriers to care, according to oncologists in a new survey by Sermo.